Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)

Cancer Immunology, Immunotherapy

Volumn 61, Issue 12, 2012, Pages 2283-2294

  Harrop, Richard ^a   Treasure, Peter ^b   De Belin, Jackie ^a   Kelleher, Michelle ^a   Bolton, Gemma ^a   Naylor, Stuart ^a   Shingler, William H ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b Peter Treasure Statistical Services Ltd   (United Kingdom)

Author keywords

5T4; Antibody; Biomarker; Inflammatory anemia; Renal cell carcinoma; Therapeutic vaccine

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; C REACTIVE PROTEIN; CALCIUM; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PLACEBO; SUNITINIB; VASCULOTROPIN;

ANEMIA; ANTIBODY RESPONSE; ARTICLE; CANCER SIZE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DISEASE MARKER; DRUG EFFICACY; HEMATOCRIT; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; KIDNEY CANCER; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MEAN CORPUSCULAR HEMOGLOBIN; METASTASIS POTENTIAL; NEUTROPHIL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STATISTICAL MODEL; THROMBOCYTE; TREATMENT RESPONSE;

ANEMIA; ANTIBODIES, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; HEMOGLOBINS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84871004671     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1302-9     Document Type: Article

References (30)

1. Hole N, Stern PL (1988) A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 57:239-246
2. Southall PJ, Boxer GM, Bagshawe KD et al (1990) Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61:89-95
3. Starzynska T, Marsh PJ, Schofield PF et al (1994) Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 69:899-902
4. Damelin M, Geles KG, Follettie MT et al (2011) Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 71:4236-4246
5. Amato RJ, Hawkins RE, Kaufman HL et al (2010) Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 16:5539-5547
6. Amato RJ, Shingler W, Goonewardena M et al (2009) Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): A phase 2 trial. J Immunother 32:765-772
7. Amato RJ, Shingler W, Naylor S et al (2008) Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: A phase II trial. Clin Cancer Res 14:7504-7510
8. Hawkins RE, Macdermott C, Shablak A et al (2009) Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother 32:424-429
9. Kaufman HL, Taback B, Sherman W et al (2009) Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 7:2
10. Elkord E, Dangoor A, Drury NL et al (2008) An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother 31:820-829
11. Harrop R, Connolly N, Redchenko I et al (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial. Clin Cancer Res 12:3416-3424
12. Harrop R, Drury N, Shingler W et al (2008) Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 57:977-986
13. Harrop R, Drury N, Shingler W et al (2007) Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13:4487-4494
14. Amato RJ, Drury N, Naylor S et al (2008) Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial. J Immunother 31:577-585
15. Harrop R, Shingler W, Kelleher M et al (2010) Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J Immunother 33:999-1005
16. Harrop R, Shingler WH, McDonald M et al (2011) MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother 60:829-837
17. Gulley JL, Arlen PM, Madan RA et al (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59:663-674
18. Gulley JL, Drake CG (2011) Immunotherapy for prostate cancer: Recent advances, lessons learned, and areas for further research. Clin Cancer Res 17:3884-3891
19. Gulley JL, Madan RA, Schlom J (2011) Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 18:e150-e157
20. Dangoor A, Lorigan P, Keilholz U et al (2010) Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 59:863-873
21. Hoos A, Britten CM, Huber C et al (2011) A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 29:867-870
22. Armstrong AJ, Eisenberger MA, Halabi S et al (2011) Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 61:549-559
23. Boehm DU, Lebrecht A, Schmidt M et al (2007) Prognostic impact of haemoglobin levels in breast cancer. Anticancer Res 27:1223-1226
24. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296
25. Ganz T, Nemeth E (2009) Iron sequestration and anemia of inflammation. Semin Hematol 46:387-393
26. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011-1023
27. Brugnara C (2003) Iron deficiency and erythropoiesis: New diagnostic approaches. Clin Chem 49:1573-1578
28. Chiarella P, Vulcano M, Bruzzo J et al (2008) Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol Immunother 57:701-718
29. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570
30. Sheng KC, Wright MD, Apostolopoulos V (2011) Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr Med Chem 18:5507-5518